Chitosan-based microneedles as a potential platform for drug delivery through the skin: Trends and regulatory aspects

Int J Biol Macromol. 2021 Aug 1:184:438-453. doi: 10.1016/j.ijbiomac.2021.06.059. Epub 2021 Jun 11.

Abstract

Microneedles (MNs) fabrication using chitosan has gained significant interest due to its ability of film-forming, biodegradability, and biocompatibility, making it suitable for topical and transdermal drug delivery. The presence of amine and hydroxyl functional groups on chitosan permits the modification with tunable properties and functionalities. In this regard, chitosan is the preferred material for fabrication of MNs because it does not produce an immune response in the body and can be tailored as per required strength and functionalities. Therefore, many researchers have attempted to use chitosan as a drug delivery vehicle for hydrophilic drugs, peptides, and hormones. In 2020, the FDA has issued "Regulatory Considerations for Microneedling Products". This official guidance is a sign for future opportunities in the development of MNs. The present review focuses on properties, and modifications of chitosan used in the fabrication of MNs. The therapeutic and diagnostic applications of different types of chitosan-based MNs have been discussed. Further, the regulatory aspects of MN-based devices, and patents related to chitosan-based MNs are discussed.

Keywords: Chitosan; Microneedles; Regulatory aspects; Skin delivery.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Chitosan / chemistry*
  • Drug Delivery Systems / instrumentation*
  • Guidelines as Topic
  • Humans
  • Legislation, Drug / organization & administration*
  • Microtechnology
  • Needles
  • United States
  • United States Food and Drug Administration

Substances

  • Chitosan